Skye Bioscience, Inc. SKYE
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
2/9
Piotroski F — financial health
-28.41
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | — | -$55.9M | — | -$43.1M | $20.0M |
| 2024 | — | -$26.6M | — | -$26.8M | $68.2M |
| 2023 | — | -$37.6M | — | -$14.0M | -$2.1M |
| 2022 | — | -$19.5M | — | -$12.8M | -$3.0M |
| 2021 | — | -$8.5M | — | -$6.6M | $5.9M |
| 2020 | — | -$6.6M | — | -$6.1M | $450,786 |
Why these scores methodology →
Piotroski F-score: 2/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -28.41 (distress)
- Working capital / assets 0.667
- Retained earnings / assets -6.6
- EBIT / assets -2.054
- Equity / liabilities 2.416
Source: SEC EDGAR filings · CIK 0001516551 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.